N550

Cabot Corporation Launches EVOLVE™ Sustainable Solutions Technology Platform Focused on Advancing Sustainable Reinforcing Carbons

Retrieved on: 
Tuesday, March 21, 2023
Automotive Manufacturing, Manufacturing, Batteries, Technology, Chemicals, Plastics, Carbon, International Sustainability Alliance, Newsweek, ASTM, IBD, Cabot Corporation, Platinum, Table tennis rubber, GHG, Multimedia, ISCC, N550, NYSE, Plant, Cabot, Corporation, Pyrolysis, EVOLVE, CO2, Renewable energy, Engineered wood, Recycling, Tire manufacturing

Cabot Corporation (NYSE: CBT) today announced the launch of EVOLVE™ Sustainable Solutions, a new technology platform for advancing sustainable reinforcing carbons.

Key Points: 
  • Cabot Corporation (NYSE: CBT) today announced the launch of EVOLVE™ Sustainable Solutions, a new technology platform for advancing sustainable reinforcing carbons.
  • View the full release here: https://www.businesswire.com/news/home/20230321005243/en/
    Increased environmental pressures are driving greater demand for sustainable reinforcing carbon solutions that support a circular, sustainable economy as well as decrease GHG emissions.
  • The introduction of EVOLVE Sustainable Solutions is an important step in Cabot’s journey to develop new ways to create materials that improve daily life and enable a more sustainable future.
  • Cabot has launched two new products powered by EVOLVE Sustainable Solutions under the recovered category, VULCAN® 7H-C circular reinforcing carbon and STERLING® SO-RC110 circular reinforcing carbon that will leverage an ISCC PLUS certified mass balance approach.

Origin Materials and Intertex Announce Partnership to Produce 100% Bio-Content Carbon Black for Rubber Compounding

Retrieved on: 
Monday, July 25, 2022
Chemicals, Plastics, Automotive Manufacturing, Environment, Manufacturing, Green Technology, Other Manufacturing, Textiles, Rubber industry in Malaysia, Carbon, Pigment, CMF, N550, Global health, Textile, Forward-looking statement, SEC, Ingate Systems, Partnership, Clothing, Probability, Compte rendu, COVID-19, Multimedia, Petroleum, NASDAQ, Economics, Plastic, Elastomer, Renewable energy, Risk management

Origin Materials, Inc. (Origin or Origin Materials) (NASDAQ: ORGN, ORGNW), the worlds leading carbon negative materials company with a mission to enable the worlds transition to sustainable materials, and Intertex World Resources, Inc. (Intertex), a leading value-added distributor of synthetic rubber, carbon black, process oils and rubber chemicals, today announced a strategic partnership to bring sustainable carbon-negative carbon black made using Origin Materials patented technology platform to the rubber compounding and plastic masterbatch industries.

Key Points: 
  • Origin Materials, Inc. (Origin or Origin Materials) (NASDAQ: ORGN, ORGNW), the worlds leading carbon negative materials company with a mission to enable the worlds transition to sustainable materials, and Intertex World Resources, Inc. (Intertex), a leading value-added distributor of synthetic rubber, carbon black, process oils and rubber chemicals, today announced a strategic partnership to bring sustainable carbon-negative carbon black made using Origin Materials patented technology platform to the rubber compounding and plastic masterbatch industries.
  • View the full release here: https://www.businesswire.com/news/home/20220725005247/en/
    As part of the partnership, Intertex signed an offtake agreement with Origin Materials to purchase sustainable carbon black.
  • Origin and Intertex will work to develop a carbon black for automotive seal customers requiring high performance carbon blacks for rubber window seals.
  • Founded in 1990, Intertex is a leading value-added distributor of synthetic rubber, carbon black, process oils, and other rubber chemicals.

Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2 Inhibitor

Retrieved on: 
Friday, October 8, 2021
Private Securities Litigation Reform Act, Twitter, Diarrhea, Neoplasm, Patient, Infrared spectroscopy correlation table, ID, Therapy, Risk, BID, N550, Cholangiocarcinoma, Retinopathy, Conference, COVID-19, Preclinical development, Protein, GLOBE, FGFR2, Safety, Precision medicine, SD, Human, QD, U.S. Securities and Exchange Commission, Hyperphosphatemia, Toxicity, Toxic leukoencephalopathy, Cancer, Security (finance), AACR, Family, Circulating tumor DNA, RPED, News, FGFR, Â, DNA, Media, Disease, Clinical trial, DLT, PR, Nasdaq, Lists of diseases, Pharmaceutical industry, Vaccine, Medical imaging

Relay Therapeutics anticipates selecting a once daily recommended Phase 2 dose and initiating expansion cohorts prior to the end of 2021.

Key Points: 
  • Relay Therapeutics anticipates selecting a once daily recommended Phase 2 dose and initiating expansion cohorts prior to the end of 2021.
  • RLY-4008 clinical data exemplifies the power of the Relay Therapeutics Dynamo platform and approach to discovering innovative medicines, said Don Bergstrom, M.D., Ph.D., executive vice president of R&D at Relay Therapeutics.
  • Together, the interim data suggest that RLY-4008 is a highly selective FGFR2 inhibitor in humans.
  • Consistent with the preclinical profile, these early clinical data support Relay Therapeutics belief that RLY-4008 has broad therapeutic potential across FGFR2 alterations and tumor types.